

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Recombinant Anti-CD39 antibody [EPR20627]

RRID:AB_2889212

Type: Antibody

Proper Citation

Abcam Cat# ab223842, RRID:AB_2889212

Antibody Information

URL: http://antibodyregistry.org/AB_2889212

Proper Citation: Abcam Cat# ab223842, RRID:AB_2889212

Target Antigen: CD39

Clonality: recombinant monoclonal

Antibody Name: Recombinant Anti-CD39 antibody [EPR20627]

Description: This recombinant monoclonal targets CD39

Clone ID: EPR20627

Antibody ID: AB_2889212

Vendor: Abcam

Catalog Number: ab223842

Record Creation Time: 20231110T031708+0000

Record Last Update: 20260829T043623+0000

Ratings and Alerts

No rating or validation information has been found for Recombinant Anti-CD39 antibody [EPR20627].

No alerts have been found for Recombinant Anti-CD39 antibody [EPR20627].

Data and Source Information

Usage and Citation Metrics

We found 11 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Sardarni UK, et al. (2026) Dietary Fat Content Influences PanIN Progression and Pancreatic Cancer Development in Mice. *Cancer research communications*, 6(5), 1036.

Li H, et al. (2025) Distinct CD8+ T cell dynamics associate with response to neoadjuvant cancer immunotherapies. *Cancer cell*, 43(4), 757.

Lee YJ, et al. (2025) Tumor-specific but immunosuppressive CD39+CD8+ T cells exhibit double-faceted roles in clear cell renal cell carcinoma. *Cell reports. Medicine*, 102360.

Tian M, et al. (2025) Deconstructing the intercellular interactome in vascular dementia with focal ischemia for therapeutic applications. *Cell*.

Ning J, et al. (2024) Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. *Cell reports. Medicine*, 5(5), 101505.

Anderson AE, et al. (2024) Characterization of AB598, a CD39 Enzymatic Inhibitory Antibody for the Treatment of Solid Tumors. *Molecular cancer therapeutics*, 23(10), 1471.

Reynolds KE, et al. (2024) Dysregulated Purinergic Signalling in Fragile X Syndrome Cortical Astrocytes. *Neuromolecular medicine*, 26(1), 36.

Li J, et al. (2024) Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer. *iScience*, 27(12), 111488.

Duan J, et al. (2023) Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma. *Cell reports. Medicine*, 4(12), 101302.

Weeden CE, et al. (2023) Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer. *Cancer cell*, 41(5), 837.

Schwabenland M, et al. (2021) Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. *Immunity*, 54(7), 1594.